11 results about "Cefoperazone" patented technology

The application relates to a compound cefoperazone and avibactam powder injection and a preparation method thereof. The compound powder injection is obtained by uniformly mixing cefoperazone hydrochloride and avibactam sodium, tabletting and crushing. When the powder injection is prepared into an injection solution, the powder injection is easy to disperse and dissolve, is convenient to use, ensures the content of cefoperazone, is not prone to produce beta-lactamase bacterial drug resistance, and has a good market application prospect.

The invention provides Kineococcus G2 and application of the Kineococcus G2 in preparation of a pigment with antioxidant activity, the Kineococcus new strain G2 is CCTCC No. M20242602, the strain is spherical, the size is 1.0 * 1.5 mu m, the optimal growth temperature is 30-37 DEG C, the pH value is 7.0-9.0, and the salt concentration is 1.0%-2.0%. The strain G2 is not sensitive to bacitracin, ciprofloxacin and norfloxacin, and is sensitive to novobiocin, polymyxin, gentamicin, piperacillin, ofloxacin, erythromycin, streptomycin, kanamycin, rifampicin, ampicillin, vancomycin, carbenicillin, chloramphenicol, tetracycline, penicillin, cefoperazone, oxacillin, amoxicillin and neomycin. Pigment generated by fermentation of the G2 strain has good antioxidant activity, and when the concentration is 10 micrograms / mL, the scavenging activity on DPPH is 25.00%, the scavenging activity on hydroxyl radicals is 80.58%, and the iron ion reducing capacity is 1.57, which are all higher than those of contrast beta-carotenoid. The application of the new Kineococcus strain G2 can lay a foundation for the research of antioxidant drugs such as medical treatment and health care product development.

The present application relates to the field of cefoperazone acid, and discloses a preparation method of cefoperazone impurity A, which comprises the following steps: (1) performing acyl chloride treatment on oxypiperazine acid in the presence of an acyl chloride reagent to generate an acyl chloride compound of oxypiperazine acid; (2) performing silylation treatment on 7-aminocephalosporanic acid in the presence of a silylation reagent to generate a silylated compound of 7-aminocephalosporanic acid; (3) reacting the acyl chloride compound of oxypiperazine acid with the silylated compound of 7-aminocephalosporanic acid to generate an intermediate compound (I); (4) hydrolyzing the intermediate compound (I) under the action of penicillin acylase to generate an intermediate compound (II); and (5) performing esterification and cyclization reaction on the intermediate compound (II) in the presence of a first crystallization solvent, a first organic solvent and a cyclization reagent to obtain the cefoperazone impurity A. The method disclosed by the present application is simple in process, and can obtain the cefoperazone impurity A with high purity, which can be used as a control sample for cefoperazone detection.

This invention provides a method for detecting related substances in cefoperazone hydrochloride particles. The method employs high-performance liquid chromatography (HPLC), wherein mobile phase A is phosphate buffer and mobile phase B is a methanol-water mixture; the chromatographic column is a column packed with octadecylsilane-bonded silica gel; and the sample is diluted with a methanol-water (1:1) mixture at pH 3-4. This method achieves separation of the four related substances in cefoperazone particles using a single analytical method (resolution > 1.5), and the use of a specific diluent ensures the stability of impurity A during detection, thereby guaranteeing the accuracy of the results.

The invention relates to the technical field of cephalosporin antibiotics, and particularly discloses a purification method of a cefoperazone acid crude product. The method comprises the following steps: mixing a solvent, a cefoperazone acid crude product, an alkaline reagent and a dispersing agent to obtain a mixed solution; the dispersing agent comprises acetone and acetonitrile; adjusting the pH value of the mixed solution to 3.0-3.5, adding a cefoperazone acid seed crystal, and growing the crystal for the first time; and adjusting the pH value of the system to be 1.5-2.0, and carrying out secondary crystal growing to obtain the cefoperazone acid. Crude cefoperazone acid products are recycled for unqualified products and mother liquor difficult to treat in existing cefoperazone acid production, S-isomer impurities most difficult to separate are specifically and efficiently removed, after purification, the S-isomer content can be reduced to 0.1% or below, the content of other impurities is smaller than 0.10%, the product purity is stabilized to be 99.5% or above, the product yield reaches up to 87%, and the method is suitable for industrial production. The recycling rate of the cefoperazone acid crude product is increased, and the economic and environment-friendly win-win effect is realized.

This invention discloses a method for preparing cefbiromate core and its application, relating to the field of compound preparation technology. The method for preparing the cefbiromate core includes the following steps: reacting 7-ACA with an active ester under alkaline conditions; after enzymatic hydrolysis and carboxyl protection, the reactants are obtained as the cefbiromate core. This method is environmentally friendly, has high production efficiency, and yields cefbiromate cores with high purity and good yield. It avoids the need for reprocessing due to the presence of certain impurities, thus improving production efficiency. The obtained cefbiromate core is suitable for preparing cefbiromate.

The invention provides nitrate reducing bacteria C381 as well as a method and application thereof. The nitrate reducing bacteria C381 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36842; the invention provides a novel oral cavity probiotic nitrate reducing bacteria C381, the nitrate reducing bacteria C381 has an inhibition effect on periodontal disease bacteria, and the nitrate reducing bacteria C381 is sensitive to antibiotics such as erythromycin, piperacillin, minocycline, doxycycline, cefazolin, tetracycline, amikacin, gentamicin, vancomycin and cefoperazone, and can be used for preparing oral cavity probiotics for treating periodontal disease bacteria. And the product has good survival ability in the oral cavity.

The invention provides bacillus C367 as well as a method and application thereof. The bacillus C367 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36841; the bacillus C367 is separated from the Inner Mongolia cheese; the bacillus C367 can be used for preparing medicines for treating or preventing periodontal diseases; the invention provides a novel oral cavity probiotic bacillus C367, the bacillus C367 has an inhibition effect on periodontal disease bacteria, and the bacillus C367 is sensitive to antibiotics such as minocycline, amikacin, tetracycline, erythromycin, cefoperazone, streptomycin, kanamycin, gentamicin, vancomycin and ceftriaxone, and has good survival ability in an oral cavity.

This invention discloses a method for determining the release rate of cefoperazone hydrochloride sustained-release formulations. The method employs a reciprocating cylinder method to determine the release rate of the cefoperazone hydrochloride sustained-release formulation, comprising the following steps: dissolving the cefoperazone hydrochloride sustained-release formulation in a first phosphate buffer solution; replacing the first phosphate buffer solution with fresh solution at different time points A to obtain multiple dissolution solutions A; storing dissolution solutions A at 2-8°C; and determining the cefoperazone hydrochloride content in dissolution solutions A. The cefoperazone hydrochloride sustained-release formulation comprises cefoperazone hydrochloride sustained-release particles. The temperature of the first phosphate buffer solution is 37.0±0.5°C, the pH is 6.7-6.9, and the volume is 240-260 mL. This invention's method can accurately determine the release rate of cefoperazone hydrochloride in in vitro experiments.

The application discloses a detection kit for simultaneously determining the concentrations of 12 kinds of antibiotic drugs in trace serum and application, the 12 kinds of antibiotics including vancomycin, meropenem, imipenem, cilastatin, trimethoprim, linezolid, voriconazole, piperacillin, cefoperazone, sulfamethoxazole, cefepime and ceftazidime; the detection kit comprises pretreatment reagents and a liquid chromatography mobile phase; the pretreatment reagents comprise a protein precipitant and purified water; the protein precipitant comprises 50v / v% of methanol and 50v / v% of acetonitrile; the liquid chromatography mobile phase comprises phase A and phase B, the phase A comprises 0.02% of formic acid and 99.98% of water, and the phase B comprises 100% of acetonitrile. The method of the application only needs 10 muL of human serum sample, and can complete the detection within 4 min, can quantitatively determine 12 kinds of antibiotics with significant structural differences, and is simple, rapid, sensitive, accurate and specific.

The application discloses a kind of adhering arrow bacteria DLW198 and application.It belongs to the technical field of antibiotic degradation.The adhering arrow bacteria DLW198 of the application can tolerate the concentration of cefoperazone is 50-250mg / L, the inoculation amount of adhering arrow bacteria is 5%-25%, the degradation temperature is 20-40 DEG C, and pH is 5-9, under the above conditions, adhering arrow bacteria can effectively degrade cefoperazone.Under the conditions of temperature 30 DEG C, pH 7, inoculation amount 20%, and rotation speed 200r / min, the degradation rate of strain DLW198 to 200mg / L cefoperazone reaches 92.98% in 16h.In addition, strain DLW198 can also degrade cephalexin, ceftriaxone sodium, cefixime and amoxicillin.The strain has higher biological safety, and will not endanger human health or pollute the environment in the application process, and has important application value.